Nektar Therapeutics (NKTR) Accounts Payables (2010 - 2026)

Nektar Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 43.78% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (down 43.78% YoY), while the FY2025 annual figure was $10.8 million, down 6.83% from the prior year.
• Accounts Payables for Q1 2026 stood at $10.0 million, down from $10.8 million in the prior quarter.
• The five-year high for Accounts Payables was $17.8 million in Q1 2025, with the low at $2.6 million in Q2 2023.
• The 5-year median for Accounts Payables is $10.0 million (2026), against an average of $9.8 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables slumped 78.79% in 2023, then surged 160.86% in 2024.
• Nektar Therapeutics' Accounts Payables stood at $13.0 million in 2022, then dropped by 24.13% to $9.8 million in 2023, then gained by 17.38% to $11.6 million in 2024, then declined by 6.83% to $10.8 million in 2025, then slipped by 6.91% to $10.0 million in 2026.
• Business Quant data shows NKTR's Accounts Payables at $10.0 million in Q1 2026, $10.8 million in Q4 2025, and $15.6 million in Q3 2025.